Basf Agricultural Solutions Seed US LLC

Bayer Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Nikolaus Pawlowski

Ernst Weber

Jan Tebbe

Fabien Poree

Bernd Laber

Michael Strerath

Gudrun Lange

Manuel Dubald

Marc Linka

Wayne Coco

Nina Wobst

Christina Thies

Sandra Geske

Heike Balven-Ross

Beatrix Stelte-Ludwig

Uwe Gritzan

Sandra Berndt

Mark Trautwein

Christian Votsmeier

Patrick Jones

Hans-Georg Lerchen

Anne-Sophie Rebstock

Yolanda Cancho Grande

Simone Greven

Sven Wittrock

Lisa Dietz

Christoph Mahlert

Stephan Märsch

Dorian Schönfeld

Oliver Von Ahsen

Katharina Filarsky

Sabine Hoff

Julian Marius Glück

Stefanie Hammer

Philipp Ellinger

Matyas Gorjanacz

Helge Roider

Wiebke Maria Nadler

Su-Yi Tseng

Christian Bertling

Pascale Buchmann

Pedro Paz

Phaik Lyn Oh

Jenny Fitting

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human,and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Methods of treatment using CCR8 antibodies

In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.

HPPD variants and methods of use

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

Growing community of inventors

Cologne, Germany

Nikolaus Pawlowski